Not investment advice. Educational platform. See Disclaimer.
NASDAQ: CGON
CG Oncology, Inc. Common stock
Healthcare | Biotechnology
No licensed closing price on file for CGON. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.
EPS (TTM)$-2.70
CG Oncology, Inc. Common stock (NASDAQ: CGON) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 17:54 UTC.
Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.
2026-04-13Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2025-07-11Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2025-01-10Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
CG Oncology, Inc. Common stock is a biotechnology company, listed on NASDAQ as CGON.
When did CGON last file with the SEC?
CG Oncology, Inc. Common stock's most recent SEC filing on record is a SCHEDULE 13G/A filed 2026-08-14. All filings link to their SEC EDGAR originals above.
Where does this data come from?
SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 17:54 UTC. This page is also available as JSON at /api/data?ticker=CGON and is emitted with FAQPage structured data for machine reading.
For you
Charts, 10-year financials, peer comparison, screening and portfolio tracking for CGON and 5,000+ tickers.
Oxford Ledge
Search